Double strike: engineered immune cells and targeted pill take on tough leukemia

NCT ID NCT07074496

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people newly diagnosed with a specific, aggressive leukemia (Ph+ ALL). It combines a single infusion of specially engineered immune cells (CAR-T cells) with a daily targeted pill (olverembatinib). The goal is to see if this powerful one-two punch can safely wipe out the cancer at the genetic level. The trial involves 20 adults and will closely monitor for side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ThisCART19A (a type of CAR-T cell therapy) and olverembatinib (a targeted cancer drug)
What this could lead to: If successful, this combination could offer a powerful upfront treatment for a hard-to-treat leukemia, potentially leading to deep and lasting remission without the need for long-term chemotherapy.
What could go wrong: This is a very early (Phase 1) and small study with only 20 people. The treatment carries risks of serious side effects, including cytokine release syndrome and nervous system problems. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) leukemia, acute lymphocytic, susceptibility to, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
RECRUITING

Suzhou, Jiangsu, 215000, China
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
RECRUITING

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.